Faculty
Faculty who are involved with the M.S. program join an official Graduate School group titled a "graduate faculty body." The Clinical Research MS graduate faculty body currently consists of 53 faculty members. Additional faculty will be added as the program needs grow and specific skills are required.
The major draws faculty from the University's schools of public health, medicine, dentistry, nursing, pharmacy, and veterinary medicine. Faculty interests range over a broad set of topics. The following table lists areas of research expertise for full-time and adjunct faculty.
|
CR Faculty/Home Department |
Research Interests |
|
Jasjit Ahluwalia, MD, MPH, MS |
Pharmacotherapy and behavior change for chronic disease, including nicotine addiction, obesity, nutrition and physical activity |
|
K. Scott Baker MD, MS |
Long-term complications in survivors of childhood cancer or after hematopoietic stem cell transplantation |
|
Gregory Beilman, MD, FACS |
Tissue energetics in hemorrhagic and septic shock; new monitoring strategies in the ICU; Novel treatments of sepsis; outcomes in ICU and surgical infections |
|
Alan Berger, MD |
Acute coronary syndromes and interventional catheterization. Utilization of reperfusion therapy for acute myocardial infarctions. |
|
Carole Bland, PhD |
Individual and institutional characteristics of research productivity, faculty development and educational program evaluation |
|
Donna Bliss, PhD, RN, FAAN |
Effects of dietary fiber therapies on fecal incontinence; nutrition support - dietary fiber, tube feeding and diarrhea; prevention of perineal dermatitis associated with incontinence |
|
Hanna Bloomfield, MD, MPH |
Health services and outcomes research, chronic disease, cardiovascular disease prevention and clinical trials |
|
Paul Bohjanen, MD, PhD |
T Lymphocyte mRNA Stability. Research focuses on the role of mRNA decay in regulating T lymphocyte activation and function. |
|
Linda Burns, MD |
Clinical trials research; hematopoietic stem cell transplantation; hematologic malignancies; immunotherapy |
|
Linda F, Carson, MD |
Clinical interests are vulvar cancer, cervical cancer, endometrial cancer and ovarian cancer; premalignant and malignant conditions of the lower genital tract, gestational trophoblastic disease, and nutrition and cancer. |
|
Jay N. Cohn, MD |
Congestive heart failure diagnosis and treatment, hypertension, early detection of CV disease, arterial compliance |
|
Allan Collins, MD |
Observational studies using large registry databases for kidney disease patients; causes and consequences of anemia and other complications of end-stage renal disease |
|
Tracie Collins, MD, MPH |
Epidemiology, process of care, and outcomes for patients with peripheral arterial disease (PAD). Long-term goals are 1) to improve outcomes for patients with PAD, 2) to eliminate racial disparities in outcomes, and 3) improve self-management behavior among patients with PAD and other chronic diseases |
|
Daniel Duprez, MD, PhD |
Clinical trials cardiology, primary and secondary prevention, arterial stiffness, lipid disorders, arterial hypertension, peripheral vascular disease, cardiovascular risk scores. New techniques for early detection of cardiovascular disease |
|
Susan Duval, PhD |
Cardiovascular and diabetes epidemiology, biostatistical methods, meta-analysis, publication bias, statistical consulting |
|
Maurice Dysken, MD |
Clinical trials with Alzheimer patients for treatment of cognitive impairment and/or behavioral problems: delirium assessment and prevention |
|
Kristine Ensrud, MD, MPH |
Epidemiology of chronic diseases with focus in osteoporosis prevention and treatment, management of menopausal symptom, sleep disorders |
|
Patricia Fontaine, MD, MS |
Cervical cancer screening. Perinatal and newborn care, including pain management for labor. Practice-based research networks. |
|
Steven S. Fu, MD, MSCE |
Improving outcomes for minority smokers |
|
Michael Garwood, PhD |
To apply theoretical formalism to describe the magnetic response phenomenon; in particular, the interaction between nuclear spins and a radiofrequency field having a variable amplitude and frequency in time. To exploit the unique properties of these frequency-modulated RF techniques to enhance sensitivity and data quality in MRI and MRS. To expose molecular properties of cancers using MRI and MRS, and to use these for making diagnoses and for evaluating and guiding cancer treatments, all non-invasively. |
|
Edward Greeno, MD |
Clinical trials involving prevention of thrombosis and in active treatment of solid tumor malignancies |
|
Richard Grimm, MD, PhD |
Clinical trials on hypertension, lipids, CV risk; women’s Health and complementary and alternative medicine |
|
Pankaj Gupta, MD |
Treatment of myelodysplastic syndromes and gastro-intestinal malignancies. Examining the role of heparan sulfate proteoglycans (HSPG) and glycosaminologycans (GAGS) in stem cell biology |
|
Dorothy Hatsukami, PhD |
Behavioral pharmacology and treatment of nicotine addiction; toxicity of tobacco products |
| Bernhard J. Hering, MD Department of Surgery |
To innovate, improve, and implement cell-based therapies to restore normoglycemia and insulin independence in individuals in whom diabetes is complicated by frequent acute or progressive chronic complications. |
|
Alan T. Hirsch, MD |
Epidemiology of peripheral arterial disease (PAD); clinical trials of PAD pharmacotherapies, endovascular interventions, and tobacco cessation interventions to improve non-coronary vascular outcomes; clinical trials of lipid and hypertension cardiovascular risk reduction interventions; evaluation of quality-of-life in vascular diseases; health economics of PAD. |
|
Hassan Ibrahim, MD, MS |
Clinical research in progressive renal disease, diabetic nephropathy and chronic renal transplant rejection |
|
Ajay Israni, MD, MS |
Molecular epidemiology and renal transplantation, outcomes in renal transplantation and end-stage renal disease |
|
Mike T. John, DDS, MPH, PhD |
Investigation of the etiology, diagnosis and classification of temporomandibular disorders and the assessment of outcomes of common oral treatments using the concept oral health-related quality of life |
|
James R. Johnson, MD |
Molecular pathogenesis of urinary tract infections, with an emphasis on the virulence properties, ecology, and phylogenetic aspects of uropathogenic E. coli; molecular epidemiology of antibiotic resistance in E. coli; virulence factors and molecular epidemiology of enterococci, including VRE |
|
Jeffrey Kahn, PhD, MPH |
Bioethics, including ethics of human subject research, ethics and genetics, ethics and biotechnology, ethics and public health |
|
Robert Kratzke, MD |
Molecular abnormalities in lung cancer and mesothelioma, focusing primarily on cell cycle regulator genes and their loss of function in cancer. |
|
Mary Jo Kreitzer, PhD, RN, FAAN |
Optimal healing environments; complementary therapies and healing practices; mindfulness-based stress reduction |
|
Frank A. Lederle, MD |
Management of abdominal aortic aneurysms, evidence-based medical decision-making, clinical trial methodology |
|
John Look, DDS, MPH, PhD |
Temporomandibular joint disorders |
|
Russell Luepker, MD, MS |
Cardiovascular disease epidemiology and clinical trials |
|
Robert D. Madoff, MD |
Analintraepithelial neoplasia, fecal incontinence, benign colorectal disease, colorectal cancer |
|
Philip McGlave, MD |
Experimental therapy for malignant and non-malignant hematologic disorders including stem cell transplantation, immunotherapy, and gene transfer. |
|
Jeffrey S. Miller, MD |
How undifferentiated stem cells develop into functioning NK cell lymphocytes; How to manipulate NK cells to treat or prevent cancer relapse. A major emphasis is on natural killer (NK) cell development. Pre-clinical and clinical studies to develop effective anti-tumor immunotherapies. |
|
Antoinette Moran, MD |
Diabetes mellitus/cystic fibrosis |
|
James Neaton, PhD |
Randomized clinical trials - HIV treatment, hypertension, and heart failure trials |
|
Joseph Neglia, MD, MPH |
Long-term effects of cancer therapy. Occurrence of second malignancies following childhood cancer. |
|
Dennis E. Niewoehner, MD |
Principal academaic effort in recent years has involved the initiation, design, and execution of clinical trials that evaluate preventative and treatment measures for chronic obstructive pulmonary disease (COPD), as increasingly important public heath problem. |
|
Mark Paller, MD, MS |
Clinical trials management; clinical research in acute renal failure, renal and electrolyte disorders |
|
Bruce Peterson, MD |
Clinical research/Hematologic malignancies |
|
Anna Petryk, MD |
Mammalian development and the molecular mechanisms underlying tissue differentiation and organogenesis. Endocrine late effects in long term survivors of cancer and/or bone marrow transplantation, |
|
Julie Ross, PhD |
Molecular epidemiology and etiology of malignancies in both children and adults, particularly in the area of leukemia |
|
David Rothenberger, MD |
Rectal cancer; Familial Colorectal cancer; Clinical research in a managed care environment |
|
Timothy Schacker, MD |
HIV transmission and nature history of Hepes Simplex Virus Infection |
|
S. Charles Schulz, MD |
Schizophrenia, borderline personality disorder, psychiatric illnesses in adolescents, brain imaging |
|
Elizabeth Seaquist, MD |
Diabetes and diabetes complications |
|
Alan Sinaiko, MD |
Blood pressure/hypertension in children and adolescents. |
|
Julia Steinberger, MD, MS |
Metabolic syndrome in youth |
|
Marie E. Steiner, MD |
Coagulation disturbances in the critically ill pediatric patient |
|
David E.R. Sutherland, MD, PHD |
Immunology and Transplantation Biology and Transplantation for Metabolic Diseases |
|
William Thomas, PhD |
Clinical trials |
|
Carolyn Torkelson, MD, MS |
Complementary/alternative medicine, women’s health, nutrition, probiotics |
|
Todd Tuttle, MD |
Clinical trials evaluating therapies for breast cancer, melanoma, and gastrointestinal malignancies |
|
Beth A. Virnig, PhD, MPH |
Access and quality of end-of-life care, cancer care and differences in care between the Medicare Fee-for service and managed care systems. |
|
Daniel Weisdorf, MD |
Clinical bone marrow transplantation and management of hematologic malignancy |
|
Tim Whelan, MD |
Diagnosis and treatment of interstitial lung diseases |
|
Mark Yeazel, MD, MPH |
Colorectal cancer screening, Childhood cancer survivors, Clinical research related to cancer prevention and detection |
|
Douglas Yee, MD |
Breast cancer: on insulin growth factors (IGF) in breast cancer, including their signaling pathways and receptors |
